RxDoctor Payments Data

Eric Flenaugh, MD

Pulmonary Disease · Atlanta, GANPI 1689674566

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (33.4%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Veran Medical Technologies, Inc. at 41.3% of the total. Reporting peaked in 2019 at $33,206 and has fallen 58.5% since, to $13,776 in 2025. Among pulmonary disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$92,724in general payments, 2019–2025

Across 363 payments — averaging $255.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Veran Medical Technologies, Inc.$38K
  • Olympus America Inc.$20K
  • Cook Medical LLC$7K
  • Olympus Medical Systems Corporation$4K
  • Cook Incorporated$4K
  • AstraZeneca$3K
  • plus $17K from 31 others
$4,677in research payments, 2019–2025

Across 4 payments — averaging $1169.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$5K

What the payments were for

  • Consulting fees$29,47032%
  • Speaking & faculty fees$22,40024%
  • Travel & lodging$30,97633%
  • Food & beverage$9,86011%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$92,724 in reported general payments places this provider in the 95th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$23,435
Medicare patients
57
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$21,418
Incruse ElliptaUmeclidinium Bromide11$3,499
Albuterol Sulfate HfaAlbuterol Sulfate46$1,439
Ventolin HfaAlbuterol Sulfate13$602
Montelukast Sodium13$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Incruse Ellipta$25$24,91743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →